Infusion Pharma Joins Speaker Line-up for Orphan Drugs and Rare Diseases 2015

LONDON - July 20, 2015 - PRLog -- SMi is delighted to announce that John Maddox, Managing Directorof Infusion Pharma Consulting LLC, has joined the speaker line-up for the 4^th annual Orphan Drugs and Rare Diseases Conference.

In his unique presentation entitled “The Importance of Building Commercial Considerations into Orphan Drug Development from the Start”, Mr. Maddox will discuss why it’s vital to build these commercial considerations. He will also address the challenge of multi-indication products and will answer the question of how to support early market development efforts.

SMi Group is delighted to present their 4th annual Orphan Drugs and Rare Diseases Conference, taking place in London, UK, on 19th – 20th October 2015. Through a series of interactive presentations and panel discussions, event attendees will be able to learn how pharmaceutical, biotech, patient organisations and academia are structuring to participate and leverage the growing orphan market.

Key topics include:

The development of ultra-orphan drugs to prevent, diagnose and treat rare diseases

Strategies for overcoming the challenges for reimbursement of orphan and ultra-orphan drugs

How to create workable partnerships for future development of drugs

For further information go to: http://www.smi-online.co.uk/2015orphandrugs3.asp

Confirmed organisations include: GW Pharmaceuticals, PSR Orphan Experts, PSR Group B.V., Shire Pharmaceuticals Limited, Cello Health Insight – London, Infusion Pharma Consulting LLC, Otsuka Europe Development and Commercialisation

Event Speakers for 2015 include:

Dr Alastair Kent OBE, Director, Genetic Alliance UK, Chair, Rare Disease UK (RDUK)
Dr Niclas Sireau, Chairman & CEO, AKU Society
Dr Tim Miller, President & CEO, Abeona Therapeutics
Dr Anne Marquet, Principal Clinical Scientist, Rare Diseases, Roche Pharma Research and Early Development
Josie Godfrey, Associate Director Highly Specialised Technologies and Topic Select, National Institute for Health and Care Excellence
Christine Lavary, Chief Executive, MPS Society UK
Dr Carlos R. Camozzi, Chief Medical Officer, Orphazyme
Michael Skynner, Head of Rare Disease External Alliances, Pfizer
David Boothe, Global Commercial Leader – GSK Rare Diseases, GSK
Dr Didier Caizergues, Head of regulatory Affairs Department, International Regulatory Affairs department, GENETHON
Stephane Demotz, Founder, DORPHAN S.A.
Tim Miller, President & CEO, Abeona Therapeutics

The event programme also includes two interactive half-day post-conference workshops:

A: Market access to orphan drugs: Controversies, trends and solutions

Workshop leader: Colette Hamilton, Managing Director, ATP Market Access

B: The rare disease patient perspective-from regulatory to clinical execution

Workshop leaders: Christa van Kan, Team Lead Clinical Execution, PSR Orphan Experts, Steve Phinder, PhD Director, Envestia Ltd, and Nicolas Sireau, PhD, Chairman and CEO, AKU Society

For further details please contact:

Fateja Begum:  fbegum@smi-online.co.uk

Contact number:  +44 (0) 20 7827 6184

4^th annual Orphan Drugs and Rare Diseases

London, UK

October 19^th-20^th, 2015

Holiday Inn Regents Park, London, UK

http://www.smi-online.co.uk/2015orphandrugs3.asp

------------------------- END --------------------------

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk